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StatinsPost-translational modiﬁcation of small GTPases by farnesyl- (FPP) and geranylgeranylpyrophosphate
(GGPP) has generated much attention due to their potential contribution to cancer, cardiovascular and
neurodegenerative diseases. Prenylated proteins have been identiﬁed in numerous cell functions and
elevated levels of FPP and GGPP have been previously proposed to occur in Alzheimer disease (AD) but have
never been quantiﬁed. In the present study, we determined if the mevalonate derived compounds FPP and
GGPP are increased in brain grey and white matter of male AD patients as compared with control samples.
This study demonstrates for the ﬁrst time that FPP and GGPP levels are signiﬁcantly elevated in human AD
grey and white matter but not cholesterol, indicating a potentially disease-speciﬁc targeting of isoprenoid
regulation independent of HMG-CoA-reductase. Further suggesting a selective disruption of FPP and GGPP
homeostasis in AD, we show that inhibition of HMG-CoA reductase in vivo signiﬁcantly reduced FPP, GGPP
and cholesterol abundance in mice with the largest effect on the isoprenoids. A tentative conclusion is that if
indeed regulation of FPP and GGPP is altered in AD brain such changes may stimulate protein prenylation and
contribute to AD neuropathophysiology.© 2009 Elsevier Inc. Open access under CC BY license.Introduction
Post-translational modiﬁcation of proteins with a C-terminal CaaX
motif by farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP) is
critical for enabling proteins to be inserted into membranes, thus
determining their localization and function (McTaggart, 2006).
Prenylated proteins include the subunits of trimeric G proteins,
protein kinases and more than 150 members of the Ras GTPase
superfamily (Takai et al., 2001). These proteins are integral compo-
nents of complex signaling networks and control diverse cellular
activities including intracellular vesicle transport, cell adhesion,
endocytosis, cytoskeletal organization, receptor signaling, cell cycle
progression and gene expression (Takai et al., 2001).
Recent experimental evidence indicates that isoprenylated
GTPases are involved in Alzheimer disease (AD) pathogenesis
(Ostrowski et al., 2007; Scheper et al., 2007). Members of the Rab
sub-family of small GTPases for example serve as cellular regulators ofEckert).
r.
irect.com).
 license.vesicular transport (Takai et al., 2001). Rab-6 is increased in AD brain
and membrane association of this geranylgeranylated protein is
dependent on presenilin 1 (PS-1) (Scheper et al., 2004, 2007). PS-1
represents an important physiological facilitator of γ-secretase
activity, which promotes the production of the pathologically
important amyloid beta protein (Aβ) (Dumanchin et al., 1999; Ridley,
2001; Scheper et al., 2004). It has also been reported that γ-secretase
action is stimulated by the isoprenoid GGPP (Urano et al., 2005), for
which FPP is the precursor. Both FPP and GGPP were found to increase
Aβ levels in H4 neuroglioma cells, expressing the Alzheimer relevant
amyloid precursor protein APP695NL (Kukar et al., 2005). Aβ
generates oxidative stress, which involves prenylated Rac1 (Lee
et al., 2002) and it was suggested that isoprenoids may regulate
different Aβ pools in the brain (Cole et al., 2005).
A straightforward prediction derived from the aforementioned
studies is that FPP and GGPP levels would be elevated in AD brains
as compared with normal neurological controls. However, this
hypothesis has not been tested and the absence of such data is in
stark contrast to the interest in the role of isoprenoids in protein
prenylation and cell function in AD (Cole and Vassar, 2006).
Impeding progress on an understanding of FPP and GGPP regulation
and consequences on protein targets have been the analytical
difﬁculties of isolation and detection sensitivity of FPP and GGPP
Fig. 1. Abbreviated mevalonate/isoprenoid/cholesterol pathway. HMG-CoA-reductase
(HMGR) activity leads to mevalonate (MVA), which is a precursor of farnesylpyropho-
sphate (FPP) formed by FPP synthase (FPPS). FPP is a branching point and serves as a
precursor of geranylgeranylpyrophosphate (GGPP) by the activity of GGPP synthase
(GGPPS). FPP is also the precursor of cholesterol.
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in human brain tissue using a newly developed and validated
ﬂuorescence HPLC method (Hooff et al., 2008). In the present study,
we determined if FPP and GGPP brain levels and the gene expression
of enzymes related to their synthesis are altered in the frontal cortex
of AD patients as compared with control samples. FPP and GGPP, like
cholesterol, are derived from mevalonate (Fig. 1) and to begin to
understand their regulation in brain, effects of inhibition of HMG-
CoA reductase on FPP and GGPP levels were determined in mouse
brain in vivo. It has been previously proposed that brain FPP and
GGPP levels are reduced by HMG-CoA reductase inhibition, but
neither have such data been reported nor has it been determined if
such inhibition has equivalent effects on FPP, GGPP and cholesterol
levels.Table 1
Patient information on control and Alzheimer subjects.
Control (n=13) Alzheimer (n=13) P value
Demographic
Age at death (years) 77.8±3.5 80.4±4.8 0.133
Gender 13 male 13 male
Histological
Postmortem interval (h) 15.0±4.4 16.5±5.0 0.433
Brain hemisphere (left:right) 0:13 3:10
Braak — Stage (I–V) – 5.1±0.7
At autopsy, brains were cut into coronal sections (2–4) and a piece of frontal cortex
tissue of each sample was freshly frozen and stored at−80 °C. Patients were classiﬁed
as AD or control cases according to CERAD. Results are shown as means±SD.Materials and methods
Chemicals and reagents
FTase and GGTase were obtained from Jena Bioscience (Jena,
Germany) and D⁎-GCVLS (dansyl gly-cys-val-leu-ser) and D⁎-GCVLL
(dansyl gly-cys-val-leu-leu) from Calbiochem (Darmstadt, Germany).
Ammonium hydroxide solution 28–30% was purchased from Alfa
Aesar (Karlsruhe, Germany), the phosphatase inhibitors Halt® and
Phosstop® from Thermo-Fisher/Piercenet (Bonn, Germany) and
Roche Diagnostics GmbH (Mannheim, Germany), respectively. All
solvents were of analytical grade or higher quality. Acetonitrile was
obtained from Carl Roth GmbH (Karlsruhe, Germany), 1-butanol, n-
hexane, 2-propanol, methanol, acetone, ammonium acetate and
assay buffer compounds: Tris–HCl, MgCl2, ZnCl2 and Na2CO3 were
obtained from Merck (Darmstadt, Germany). FPP, GGPP, octyl-β-D-
glucopyranoside and dithiothreitol were from Sigma-Aldrich
(Schnelldorf, Germany). Millipore water was used for all solutions
(Schwalbach, Germany).Human brain samples
Postmortem tissue from the frontal cortex was obtained from the
Human Brain and Spinal Fluid Resource Center, VA West Los Angeles
Healthcare Center, 11301 Wilshire Blvd. Los Angeles, CA 90073 which
is sponsored by NIH-NINDS/NIMH, National Multiple Sclerosis
Society and the Department of Veterans Affairs. In this initial study
of FPP and GGPP levels, brain grey and white matter of the cerebral
cortex was examined. Recent studies in AD patients indicate changes
in grey matter associated with hypometabolism, speciﬁc neuropsy-
chiatric symptoms and behavior (Bruen et al., 2008; Chetelat et al.,
2008). However, to conﬁrm the speciﬁcity of the isoprenoid elevation,
we additionally measured FPP, GGPP, and cholesterol levels in the
white matter of the same samples. At autopsy, brains were cut into
coronal sections (2–4) and a sample of frontal cortex tissue of each
sample was frozen and stored at −80 °C. Patients with AD were
classiﬁed according to the criteria of the Consortium to Establish a
Registry for AD (CERAD) and Braak stages. Controls were neurological
normal. The donor age varied between 70 and 88 years and the
average post mortem interval (PMI) was 15.5 h (see Table 1). No
correlation between individual PMI and FPP or GGPP levels were
found (data not shown). For sample preparation, a small piece of
frozen cortex was immediately dissected into grey and white matter
and homogenized.
Western blot analysis
For NeuN protein determination, samples were prepared by
diluting 15 μg protein with the reducing agent (10×) and loading
buffer (4×). After denaturation for 10 min at 95 °C, the samples were
electrophoretically separated on a 4–12% NuPage Bis/Tris gel
(Invitrogen, Germany) for 40 min at 180 V and then transferred on a
PVDF membrane for 120 min at 30 V and incubated with the primary
antibodies anti-NeuN (MAB377, Millipore, Germany), anti-GAPDH
(MAB374, Millipore, Germany), followed by secondary antibodies
(Calbiochem, Germany) conjugated to horseradish peroxidase and
processed for visualization by ECL® reagent (Amersham Bioscience).
Band analysis was performed using Bio-Rad's Quantity One Software.
Tissue preparation and HPLC analysis
Brain tissue preparation and FPP and GGPP determination have
previously been described by our group (Hooff et al., 2008). Brieﬂy,
each brain tissue sample was homogenized with a rotor-stator
homogenizer at 1100 rpm in 100 mM Tris buffer (pH 8.5) containing
5 μL Halt® and 10 μL Phosstop® phosphatase inhibitors. The
homogenate was vigorously mixed with 1 mL 100 mM Tris buffer
(pH 8.5). A 50 μL aliquot from the homogenate was retained for
protein and cholesterol determination and then spiked with 15 μL
2.8 μM solution of 5-(dimethylamino)naphthalene-1-(4-nonylphe-
nol)-sulfonic acid ester used as the internal standard (IS). Themixture
Fig. 3. Elevated FPP and GGPP levels in the frontal cortex grey matter of male AD brain
compared with controls. (A) Representative chromatographic overlay of grey matter
brain samples. Upper trace: AD sample; middle trace: control sample; lower trace:
blank sample. Peak labeling: ‘FPP’ and ‘GGPP’ stand for the respective dansyl-labeled
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many) and after 15 min eluted with a total of 6 mL of a 1-butanol–
ammoniumhydroxide–watermixture (10:1:2, v/v/v). The ﬁltratewas
centrifuged for 10 min at 29,000 ×g to remove precipitated proteins.
The supernatant was evaporated under reduced pressure and
dissolved again in 5 mL 5% methanol. After sonication, the solution
was applied to Oasis® HLB (3 cc; 60 mg) solid-phase extraction
cartridges from Waters (Eschborn, Germany) previously conditioned
with n-hexane, 2-propanol and methanol. The extract was washed
with a 2% methanol solution and ﬁnally eluted with an ammonium
hydroxide–propanol–n-hexane mixture (1:7:12, v/v/v). The ﬁltrate
was vacuum-dried to be re-dissolved in assay buffer for the enzymatic
reaction. The pre-column enzymatic attachment of dansyl-labeled
pentapeptides to FPP and GGPP allows a highly sensitive HPLC
ﬂuorescence detection (HPLC-FLD).
For pre-column dansyl-labeling, the dried residue was dissolved in
44 μL Tris–HCl assay buffer (Tong et al., 2005) and spikedwith 2 μL of a
50 μM solution of D⁎-GCVLS and D⁎-GCVLL (dansyl-labeled peptides)
and 250 ng FTase and GGTase, respectively. Themixturewas incubated
at 37 °C in an Eppendorf thermomixer comfort (Wesseling-Berzdorf,
Germany) programmed for 90 min (per minute: 5 s; 500 rpm). After
stopping the reaction, the mixture was centrifuged (4 °C; 15,000 ×g;
5 min) prior to HPLC-FLD analysis. The chromatographic separation
was carried out on a Jasco HPLC-system (LG-980-02, PU-980, AS-950;
Gross-Umstadt, Germany) with a gradient elution on an Ascentis®
Express C-18 reversed-phase analytical column from Supelco
(150×2.1mm, 2.7 μm;Munich, Germany) protected by a Phenomenex
Security guard column (C-18, 4×2.0 mm; Aschaffenburg, Germany).
Two solvents were used for gradient elution: solvent A, 20 mM
ammonium acetate in 40% acetonitrile and solvent B, 20 mM
ammonium acetate in 90% acetonitrile. The gradient was initiated at
35% solvent B for 1.5 min, subsequently ramped linearly to 100%
within 6.5 min, held for 6 min and then brought back to 35% solvent B
within 2 min. The total run time was 20 minwith a constant ﬂow rate
of 0.5 mL/min at 20 °C. The labeled analytes were monitored by a
ﬂuorescence detector (Gilson, Middleton, USA) set at an excitationFig. 2. Preparation of brain tissue from control and AD samples. (A) At autopsy, a picture
was taken of each sample showing the excision area and a coronal section is indicated.
(B) Quality of separation of grey fromwhitematter was conﬁrmed by enrichment of the
protein NeuN, which is a marker of neuronal cell bodies. Protein abundance was
determined byWestern analysis as described in theMaterials andmethods section. Five
samples of each tissue section were used for the protein analysis.
isoprenoids. (B) Endogenous FPP and GGPP levels in human brain grey matter in the
control and AD group. Results are shown as means±SEM, ⁎pb0.05; n=13 for each
group.wavelength of 340 nm and 525 nm for emission. The retention times
for the labeled FPP and GGPP were 4.1 min and 11.0 min, respectively
and 12.1 min for the internal standard.
Simvastatin administration to mice
Simvastatin was administered to mice as previously reported
(Johnson-Anuna et al., 2005). C57BL/6J mice (16 to 21 g) were
obtained from Janvier, Le Genest, France. Mice were maintained on a
12-h dark–light cycle with pelleted food and tap water ad libitum. All
experimentswere carried out according to the European Communities
Council Directive (86/609/EEC) by individuals with appropriate
training and experience. Statin suspension was prepared daily in
0.2% (w/v) aqueous agarose gel giving a ﬁnal concentration of 10 mg
simvastatin/mL. Animals received 50 mg simvastatin/kg b.w. daily for
21 days or vehicle by oral gavage (diameter: 1 mm) and a maximal
application volume of 0.5mL. This treatment regimewas chosen, since
according to our previous work a signiﬁcant reduction of brain
cholesterol levels without any toxicological effects, e.g. apoptosis, was
observed (Johnson-Anuna et al., 2005; Franke et al., 2007). At the end
of the study, animals were euthanized by cervical displacement 2 h
after the last drug treatment. The cerebrumwas removed, snap frozen
in liquid nitrogen, and stored at−80 °C prior to isolation and analysis.
For the isolation, half of a hemisphere was treated as described in the
preparation procedures of the human brain samples and analyzed
accordingly.
Fig. 4. Gene expression of the FPP and GGPP synthase in human AD and control brain
samples. Gene expressionwas determined by qRT-PCR as described in theMaterials and
methods section. Data were normalized to GAPDH and results are shown as means±
SEM; ⁎pb0.05; n=10 for each group.
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Protein concentrationsweremeasured using the BCA Protein Assay
Kit from Thermo-Fisher/Pierce (Bonn, Germany). Samples were
measured in triplicates. Total cholesterol levels were determined
enzymatically, using the CHOD-PAP method (Roche Diagnostics
GmbH, Mannheim, Germany).
Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA isolation
Brain tissue samples were homogenized in 1 ml of Invitrogen's
TRIzol® reagent. The remaining isolation procedure was performed in
accordance to the manufacturer's instructions. The resulting RNA was
re-suspended in nuclease-free water.
Reverse transcription
RNA concentration was determined by measuring the absorbance
at 260 nm. Known amounts of RNA were then reverse-transcribed
using Bio-Rad's iScript™ cDNA synthesis kit according to manufac-
turer's instructions, which resulted in an equivalent amount of cDNA.
Primer design
Internal primers were designed for each of the targets in question.
The NCBI's Entrez Gene database was the source of the nucleotide
sequences of each gene. Using the BLAST program, intron/exon
borders were identiﬁed and primers were designed to amplify around
these regions to eliminate ampliﬁcation of genomic DNA rather than
the desired cDNA. Primer sequences were generated using MIT's
program “Primer3”. Primer pairs are as follows:
GAPDH: left 5′- GAA ATC CCA TCA CCA TCT TCC -3′
right 5′- ATG GTT CAC ACC CAT GAC G -3′
200 base pair product
HMGR: left 5′- GAG GCA TTT GAC AGC ACT AGC -3′
right 5′- TGC ATT TCA GGG AAA TAC TCG -3′
179 base pair product
FPPS: left 5′- GAA GAT CCT GCT GGA GAT GG -3′
right 5′- GTT GTC CTG GAT GTC AGT GC -3′
109 base pair product
GGPPS: left 5′- CTA TCT GGG CAG TTC CAA GC -3′
right 5′- GAC TTC AGT GAG GGT GTT TCC -3′
127 base pair product.
Primers were tested in a RT-PCR experiment using Invitrogen's
SuperScript™ III One-Step RT-PCR System. The reaction products were
run on an agarose gel containing ethidium bromide and imaged under
UV light to verify that the intended targets were being ampliﬁed.
Real-time quantitative PCR
Relative abundance of mRNA was measured through real-time
analysis using Invitrogen's SYBR® GreenER™ qPCR SuperMix. Ther-
mal cycles were programmed according to the manufacturer's
instructions with annealing temperatures of 56.8 °C, 57.0 °C, 56.5 °C,
and 58.5 °C for HMGR, FPPS, and GGPPS primers respectively. In each
50μl reaction, there were 100 ng of cDNA template and a 200 nM
concentration of left and right primers. GAPDH was used as a
reference gene to normalize the data for each experiment and
therefore gene fold expression was determined using ΔΔCT
calculations.
Statistics
All data are expressed as mean values±standard error of themean
(SEM) unless stated otherwise. For direct comparison of differencesbetween two groups, students' t-test was calculated. All calculations
were performed with GraphPad Prism version 5.00 for Mac, GraphPad
software, San Diego, USA.
Results
The isoprenoids FPP and GGPP were determined simultaneously
using HPLC-FLD in the frontal cortex of male AD patients and age-
related controls. Brain grey and white matter of the cerebral cortex
was examined in this initial study of FPP and GGPP levels. Changes in
greymatter of AD patient have been reported recently to be associated
with hypometabolism, speciﬁc neuropsychiatric symptoms and
behavior (Bruen et al., 2008; Chételat et al., 2008). Purity of both,
the grey and white matter preparation was conﬁrmed by enrichment
of the neuronal cell nucleus marker protein NeuN (Fig. 2).
This study shows for the ﬁrst time FPP and GGPP levels in brain
tissue of AD patients and normal neurologic controls. FPP and GGPP
levels were determined by HPLC-FLD and representative chromato-
grams are shown in Fig. 3A. It can be seen in Fig. 3B that GGPP levels
were signiﬁcantly higher in brain tissue of AD patients (56%) as
compared with control samples. FPP levels were also signiﬁcantly
higher in the AD brain tissue 36% (Fig. 3B). In both AD patients and
controls, GGPP levels were markedly higher than FPP levels and that
ﬁnding is consistent with two recent reports in mouse brain and
normal human brain (Hooff et al., 2008; Tong et al., 2008).
FPP synthase and GGPP synthase are two genes whose protein
products synthesize FPP and GGPP. Gene expression of FPP synthase
and GGPP synthase were determined in brain tissue of the AD and
control samples by qRT-PCR. The increase in FPP levels in the frontal
cortex of AD brain was associated with a signiﬁcant up-regulation of
FPP synthase gene expression as seen in Fig. 4. GGPPS mRNA levels
were increased but differences did not reach signiﬁcance (Fig. 4). FPP
and GGPP levels may be controlled by enhanced speciﬁc activity of the
two synthases rather than by enhanced production of mevalonate due
to up-regulation of HMGR.
FPP serves as a precursor of both GGPP and cholesterol (Fig. 1). Our
data show signiﬁcantly increased levels of FPP and GGPP in brain
tissue of AD patients as shown in Fig. 3B. On the other hand as noted in
Fig. 5, cholesterol levels and gene expression of HMG-CoA reductase
were similar in AD and control samples. Taken together these results
indicate that homeostasis of FPP and GGPP but not cholesterol is
speciﬁcally targeted in brain tissue of AD patients. The speciﬁcity of
the isoprenoid elevation is further supported by similar observations
inwhite matter brain tissue (Fig. 6A). Here the same AD brains show a
59% and 43% elevation for GGPP and FPP, respectively. Again this
Fig. 5. Cholesterol levels and HMG-CoA reductase gene expression in brain tissue of AD
and control subjects. (A) Cholesterol levels in brain tissue of control and AD samples;
n=13 for each group. (B) Gene expression of HMG-CoA reductase (HMGR) in brain
tissue of controls and AD samples. Gene expression was determined in grey matter by
qRT-PCR as described in the Materials and methods section. Data were normalized to
GAPDH and results are shown as means±SEM; n=10 for each group.
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concentration (Fig. 6B).
To establish if FPP and GGPP regulation is more susceptible to
perturbation than cholesterol, we determined FPP, GGPP and choles-
terol levels in brains of mice treated with the HMG-CoA reductase
inhibitor, simvastatin. It has been previously proposed that statin
treatment would reduce brain FPP and GGPP levels (Cole et al., 2005),Fig. 6. Elevated FPP and GGPP levels in the frontal cortex white matter of male AD brain
compared with controls. (A) Endogenous FPP and GGPP levels in human brain white
matter (B) Cholesterol levels in brain tissue of control and AD samples; n=13 for each
group. Results are shown as means±SEM, ⁎pb0.05; n=13 for each group.
Fig. 7. Brain FPP, GGPP and cholesterol levels in mice treated with the HMG-CoA
reductase inhibitor simvastatin. (A) Representative chromatographic overlay of mouse
brain samples. Upper trace: control, middle trace: simvastatin treated sample and lower
trace: blank sample. (B) FPP and GGPP levels in the cerebrum of control and simvastatin
treated mice. (C) Brain cholesterol levels in control and simvastatin treated mice.
Results are shown as means±SEM; ⁎⁎⁎pb0.001, ⁎pb0.01 and⁎pb0.05; n=6 for each
group.but such data have not been reported. FPP and GGPP levels were
determined by HPLC-FLD and representative chromatograms are
shown in Fig. 7A. Data in Fig. 7B show that inhibition of HMG-CoA
reductase signiﬁcantly reduced FPP and GGPP by 52% and 33%,
respectively. Cholesterol levels were also signiﬁcantly reduced but to
a lower extent (22%) as shown in Fig. 7C. In AD brain, FPP and GGPP
levels are elevated (Fig. 3B) but cholesterol levels and HMG-CoA
reductase gene expression remain unaffected (Fig. 5A). In contrast,
perturbation of HMG-CoA reductase alters both isoprenoids and
cholestrol levels, albeit with differences in magnitude (Figs. 7B, C).
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which may not involve HMG-CoA reductase.Discussion
The mevalonate/isoprenoid/cholesterol pathway has generated
much attention in AD (Cole and Vassar, 2006; Scheper et al., 2007). Of
particular interest has been the proposed involvement of the two
isoprenoids FPP and GGPP via their function in prenylating small
GTPases. One of the protective effects of statins in brain has been
attributed to a reduction in FPP and GGPP levels (Cole and Vassar,
2006; McTaggart, 2006). In spite of the keen interest in isoprenoids
and AD, evidence supporting involvement of isoprenoids has only
been indirect due to a lack of a quantitative analytical method for
determining FPP and GGPP levels. This study provides for the ﬁrst time
data indicating that homeostasis of FPP and GGPP but not cholesterol
is speciﬁcally targeted in brain tissue of male AD patients. Another
important ﬁnding of this study is that we show for the ﬁrst time
effects of HMG-CoA reducatse inhibition on FPP and GGPP levels in
brains of mice chronically treated with simvastatin.
Results of this study suggest that isoprenoid regulation may be
speciﬁcally altered in AD. This conclusion is based on the following.
Both FPP and GGPP levels were signiﬁcantly higher in brain tissue of
male AD patients as compared with male control samples. Brain
cholesterol levels on the other hand did not differ between the two
groups. HMG-CoA reductase gene expressionwas similar between the
AD and control groups. However, when HMG-CoA reductase was
inhibited, FPP, GGPP and cholesterol levels were signiﬁcantly reduced
in brain tissue of mice chronically treated with simvastatin. Finally,
gene expression of FPPS was signiﬁcantly elevated in AD brain
samples compared to control brain samples. The up-regulation of FPPS
is a key ﬁnding because it is a precursor of both GGPP and cholesterol
(Fig. 1).
Regulation of FPP and GGPP is not as well-understood as
cholesterol regulation and this especially applies to the brain. Low
cellular cholesterol levels are sensed by the sterol regulatory element-
binding protein-cleavage activating protein (SCAP), which in turn
triggers a cascade of events ultimately leading to the up-regulation of
the HMG-CoA reductase and increased mevalonate production
(reviewed in Hampton, 2002). Mevalonate is the upstream precursor
of several products including FPP. Synthesis of FPP involves the
enzyme FPPS and condensation reactions of isopentenyl-5-PP and
geranyl-PP. As shown in the present study, both FPP levels and FPPS
gene expression were elevated in male AD brains. What has not been
clearly established is if changes in FPP levels are detected by SCAP
leading to the activation of the sterol regulatory element-binding
protein-2 (SREBP-2). In CaCo-2 colon epithelial cells, addition of
exogenous FPP did not alter mature SREBP-2 abundance in mevalo-
nate depleted cells by lovastatin whereas adding back mevalonate
counteracted effects of lovastatin on mature SREBP-2 (Murthy et al.,
2005). Based on elevated FPP levels and FPPS gene expression in
contrast to unchanged cholesterol levels and HMG-CoA reductase
gene expression, a tentative conclusion is that the increase in FPP
levels in AD brain may not involve the SCAP/SREBP-2 pathway.
GGPP levels but not cholesterol levels were signiﬁcantly higher in
AD brain. FPP serves as a precursor of both GGPP and cholesterol. One
interpretation of the data is a possible shunting of FPP to GGPP and
away from cholesterol. While gene expression of GGPP synthase was
higher in AD samples than controls it did not reach signiﬁcance. It is
possible in the case of GGPP that enzymatic activity of GGPP synthase
may be a critical regulatory contributor to its synthesis. The stimulus
for the increase in GGPP as well as FPP levels in AD brain tissue is
unclear. A speculative explanation may reside in proteins that are
prenylated by the two isoprenoids. It was reported that both FPP and
GGPP levels were increased when reticulocyte cytosol was incubatedwith recombinant protein substrates for FPP and GGPP prenylation,
respectively (Lutz et al., 1992).
GGPP levels were higher than FPP levels in both the male AD and
control brain samples and mouse brain samples. Those results are
consistent with the recent reports on FPP and GGPP levels in mouse
brain (Tong et al., 2008) and normal human brain tissue (Hooff et al.,
2008). An explanation for such differences is not well-understood in
any tissue and calls attention to the need for future studies. There is
some evidence that more proteins are prenylated by GGPP than FPP
(Roskoski, 2003) but at the same time the utilization of FPP is much
greater than GGPP owing to it serving as a precursor for cholesterol,
GGPP and longer chain isoprenoids.
For the ﬁrst time, effects of inhibition of HMG-CoA reductase by a
statin on brain FPP and GGPP levels were observed. It has been
previously proposed (Cole and Vassar, 2006) that HMG-CoA reductase
inhibition would reduce brain FPP and GGPP levels but such data had
not been reported due to analytical difﬁculties of isolation and
detection sensitivity of FPP and GGPP (Hooff et al., 2008). We show in
mouse brain that simvastatin had a greater effect on reducing FPP
levels followed by reductions in GGPP and cholesterol levels. It would
appear that HMG-CoA reductase inhibition does not have an equal
effect on the downstream products of mevalonate. The consequences
of these differential effects on isoprenoids and cholesterol on cell
function are unclear. One possibility is that there is a gradient of
cellular effects based on the magnitude of reduction in the individual
lipids with FPP associated cell function more affected.
In summary, the results of the current study show that FPP and
GGPP levels in grey and white matter were elevated in male AD brain
tissue. While further work is needed to unequivocally demonstrate
that FPP and GGPP regulation is altered in AD including studies
examining brain tissue of other neurodegenerative diseases, the
present ﬁndings suggest that abundance of prenylated small GTPases
may be increased in AD (Cole and Vassar, 2006; Scheper et al., 2007).
Also, these ﬁndings may have utility in the development of new drugs
similar to bisphosphonates which inhibit FPP synthase but that could
pass the blood brain-barrier. Finally, the speciﬁc increase in iso-
prenoids in the male AD brain but not cholesterol may help to explain
the varying clinical effects of statins on treating AD (Li et al., 2007;
Sparks et al., 2008; Zhou et al., 2007).
Acknowledgments
This work was supported in part by the Hanna Bragard-Apfel
foundation, the Human Brain and Spinal Fluid Resource Center, West
Los Angeles, USA, the, Medical Research Council, NIH grants AG23524,
AG18357 and the Department of Veterans Affairs.
References
Bruen, P.D., 2008. Neuroanatomical correlates of neuropsychiatric symptoms in
Alzheimer's disease. Brain 131, 2455–2463.
Chetelat, G., 2008. Direct voxel-based comparison between grey matter hypometabo-
lism and atrophy in Alzheimer's disease. Brain 131, 60–71.
Cole, S.L., Vassar, R., 2006. Isoprenoids and Alzheimer's disease: a complex relationship.
Neurobiol. Dis. 22, 209–222.
Cole, S.L., 2005. Statins cause intracellular accumulation of APP, beta-secretase cleaved
fragments, and Abeta via an isoprenoid-dependent mechanism. J. Biol. Chem. 280,
18755–18770.
Dumanchin, C., 1999. Presenilins interact with Rab11, a small GTPase involved in the
regulation of vesicular transport. Hum. Mol. Genet. 8, 1263–1269.
Franke, C., 2007. Bcl-2 upregulation and neuroprotection in guinea pig brain following
chronic simvastatin treatment. Neurobiol. Dis. 25, 438–445.
Hampton, R.Y., 2002. Proteolysis and sterol regulation. Annu. Rev. Cell Dev. Biol. 18,
345–378.
Hooff, G.P., 2008. Isoprenoid quantitation in human brain tissue: a validated HPLC-
ﬂuorescence detection method for endogenous farnesyl- (FPP) and geranylger-
anylpyrophosphate (GGPP). Anal. Bioanal. Chem. 392, 673–680.
Johnson-Anuna, L.N., 2005. Chronic administration of statins alters multiple gene
expression patterns inmouse cerebral cortex. J. Pharmacol. Exp. Ther. 312, 786–793.
Kukar, T., 2005. Diverse compounds mimic Alzheimer disease-causing mutations by
augmenting Abeta42 production. Nat. Med. 11, 545–550.
257G.P. Eckert et al. / Neurobiology of Disease 35 (2009) 251–257Lee, M., 2002. Implication of the small GTPase Rac1 in the generation of reactive oxygen
species in response to beta-amyloid in C6 astroglioma cells. Biochem. J. 366, 937–943.
Li, G., 2007. Statin therapy is associated with reduced neuropathologic changes of
Alzheimer disease. Neurology 69, 878–885.
Lutz, R.J., 1992. Feedback inhibition of polyisoprenyl pyrophosphate synthesis from
mevalonate invitro. Implications for proteinprenylation. J. Biol. Chem. 267, 7983–7986.
McTaggart, S.J., 2006. Isoprenylated proteins. Cell Mol. Life Sci. 63, 255–267.
Murthy, S., 2005. Regulation of fatty acid synthesis by farnesyl pyrophosphate. J. Biol.
Chem. 280, 41793–41804.
Ostrowski, S.M., 2007. Statins reduce amyloid-beta production through inhibition of
protein isoprenylation. J. Biol. Chem. 282, 26832–26844.
Ridley, A.J., 2001. Rho proteins: linking signaling with membrane trafﬁcking. Trafﬁc 2,
303–310.
Roskoski Jr., R., 2003. Protein prenylation: a pivotal posttranslational process. Biochem.
Biophys. Res. Commun. 303, 1–7.Scheper, W., 2004. Rab6 membrane association is dependent of Presenilin 1 and cellular
phosphorylation events. Brain Res. Mol. Brain Res. 122, 17–23.
Scheper, W., 2007. Rab6 is increased in Alzheimer's disease brain and correlates with
endoplasmic reticulum stress. Neuropathol. Appl. Neurobiol. 33, 523–532.
Sparks, D.L., 2008. Reduced risk of incident AD with elective statin use in a clinical trial
cohort. Curr. Alzheimer Res. 5, 416–421.
Takai, Y., 2001. Small GTP-binding proteins. Physiol. Rev. 81, 153–208.
Tong, H., 2008. Quantitative determination of farnesyl and geranylgeranyl diphosphate
levels in mammalian tissue. Anal. Biochem. 378, 138–143.
Tong, H., 2005. Simultaneous determination of farnesyl and geranylgeranyl pyropho-
sphate levels in cultured cells. Anal. Biochem. 336, 51–59.
Urano, Y., 2005. Association of active gamma-secretase complex with lipid rafts. J. Lipid.
Res. 46, 904–912.
Zhou, B., 2007. Prevention and treatment of dementia or Alzheimer's disease by statins:
a meta-analysis. Dement. Geriatr. Cogn. Disord. 23, 194–201.
